We also found a decrease in prescriptions of non-recommended drugs, such as NSAIDs, in CKD stage 4–5, along with a reduction in the dual use of renin–angiotensin system blockers (ACE inhibitors and ARBs) and no difference in NSAID prescriptions among patients seen by kidney specialists or GPs. Here, REN is linked to chronic kidney disease.